{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019194","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.823636+00:00","generated_at":"2026-06-07T23:53:54.181846+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products","bullets":["Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.","Initial term from Nov 13, 2023 to Nov 13, 2028; auto-renews for successive 3-year terms.","Company must purchase 100% of its requirements for covered products from Halo, except for own manufacturing.","Company supplies active ingredients; Halo handles manufacturing, QC, packaging, and validation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019194","json":"https://secwatch.observer/filing/0001558370-23-019194.json","markdown":"https://secwatch.observer/filing/0001558370-23-019194.md","text":"https://secwatch.observer/filing/0001558370-23-019194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/0001558370-23-019194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/aytu-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:53:54.181846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c1472803cfa78e53ada3b3722a575e347e68a6e","claim":"AYTU BIOPHARMA, INC entered into Commercial Manufacturing Services Agreement with Halo Pharmaceutical, Inc. (effective 2023-11-13).","evidence_excerpt":"On November 13, 2023, Aytu BioPharma, Inc. (the “ Company ”) entered into a Commercial Manufacturing Services Agreement (the “ Agreement ”), with Halo Pharmaceutical, Inc. (“ Halo ”), pursuant to which Halo will manufacture Adzenys XR ODT® and Cotempla XR ODT® products for the Company at Halo’s manufacturing facility.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/0001558370-23-019194-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Halo Pharmaceutical, Inc."},{"label":"Effective","value":"2023-11-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}